Immune thrombocytopenia (ITP) is an autoimmune dysfunctional disorder of the blood system characterized by bleeding. Secondary bleeding, such as skin, mucosal and intracranial bleeding, is commonly thought to occur when platelet counts are less than 30 × 109/L. Since in pediatric patients, ITP is generally only an acute condition that recovers spontaneously within a few weeks, chronic ITP patients are predominantly adults. Patients usually present with platelet disorders in early adulthood, and the incidence and severity of ITP increases with age. The treatment of refractory ITP in Wuhan Union Medical College Hospital, Department of Hematology, is very difficult, and the existing sub-methods are not curative and often have significant side effects. Two drugs are currently available. One is Nplate®, which is used for subcutaneous injections. It is particularly indicated for patients who have relapsed after splenectomy. It was approved by the FDA on August 22, 2008, for the long-term treatment of adult patients with chronic ITP. The other is Eltrombopag, the world’s first small molecule TPO mimetic developed by GlaxoSmithKline, which is orally absorbed and was approved by the FDA on November 20, 2008 for the treatment of thrombocytopenia in patients with chronic ITP and chronic hepatitis C treated with interferon-based therapy, and is popular because of its convenience of administration and low price. Currently, our hospital is conducting a clinical study of the domestic TPO mimetic Hetropa, and patients meeting the following criteria can apply for enrollment: 1) age 18 to 65 years old, with no restriction on gender; 2) clinical diagnosis of chronic immune thrombocytopenia before the trial; 3) diagnosis of ITP confirmed by bone marrow examination within the last 3 months or during the screening period, excluding myelodysplastic syndrome (MDS), immune diseases such as systemic SLE, early aplastic anemia (AA), atypical remitting disease, thrombotic thrombocytopenic purpura (TTP), and other secondary thrombocytopenia (STP) due to various causes. 4) Platelet count (PLT) < 30 × 109/L, hemoglobin (Hgb) within the normal range, and neutrophils ≥ 1.5 × 109/L measured on average twice during the screening period × 109/L; 5) Prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (APTT) activity must be between 80% and 120%, never in a hypercoagulable state; 6) Understand the study procedures and voluntarily sign the informed consent in writing. Contact Information 7F, Department of Hematology, Wuhan Union Medical College Hospital 027-85726007 or Mei Heng